VRN 11
Alternative Names: VRN-11; VRN-110755Latest Information Update: 01 Jan 2026
At a glance
- Originator Voronoi
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
Most Recent Events
- 22 Oct 2025 Efficacy, adverse events and pharmacokinetic data from a phase I trial in Non small cell lung cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC 2025)
- 22 Oct 2025 Voronoi plans a phase Ib/II trial for Non-small lung cancer (Monotherapy, Combination therapy, Late-stage disease, Second-line therapy or greater) (PO)
- 27 Aug 2025 Phase-I clinical trials in Non-small cell lung cancer (In volunteers) in Australia (PO) (NCT07141381)